Longboard Pharmaceuticals Inc (LBPH) Stock News

Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt

Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value.

Mentions: FYBR BLCO APO NVAX ...

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.

/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) and its board of...

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags

S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day.

Mentions: APO USAP AMPS BHC ...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders

Mentions: ARC

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record

Lundbeck will buy Longboard Pharmaceuticals in a deal slated to close in the fourth quarter.

Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

LBPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders

Lundbeck to Buy Longboard Pharmaceuticals in $2.6 Billion Deal

Danish pharmaceutical company H. Lundbeck A/S has agreed to acquire Longboard Pharmaceuticals Inc in a deal with an equity value of $2.6 billion.

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September

Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1